Introduction
Some studies have shown that exercise increases expression, phosphorylation and activation of peroxisome proliferator-activated receptor gamma co-activator 1α (PGC-1α) in skeletal muscle (Bostrom et al., 2012; Goto et al., 2000; Pilegaard et al., 2003) . PGC-1α generates protein complexes with transcription factors and thus mediates the transcription of genes associated with cellular metabolism, as well as genes that encode proteins with autocrine, paracrine and endocrine actions, known as myokines (Pedersen, 2013; Schnyder and Handschin, 2015) . PGC-1α drives the transcription of FNDC5 (fibronectin type III domain-containing protein 5), whose aminoacid sequence is posteriorly cleaved and glycosylated to form irisin (Bostrom et al., 2012; Schumacher et al., 2013) . Bostrom et al. (2012) reported for the first time that this 112 amino acid residue protein is released from skeletal muscle during exercise. This myokine is synthesized mainly in the muscle tissue, but is also found in blood, cerebrospinal fluid (CSF), cerebellum Purkinje cells, intercellular nerve endings, neuron, and neuroglia (Aydin et al., 2014; Bostrom et al., 2012; Dun et al., 2013; Gur et al., 2017; Piya et al., 2014) .
In humans, the blood irisin level was ∼3.6 ng/ml in sedentary individuals, increasing up to ∼4.3 ng/ml in individuals undergoing aerobic interval training (Jedrychowski et al., 2015) . In addition, a positive linear correlation between CSF irisin and serum irisin was reported in human subjects, suggesting that irisin found in CSF may be derived from the periphery (Piya et al., 2014) . Previous works suggest that irisin is responsible for the physical exercise effect in some rodent models of neuropathologies, including cerebral ischemia and depression (Li et al., 2017; Wang and Pan, 2016) . Furthermore, the overexpression of irisin and FNDC5 is associated with neuroplasticity, since they may modulate neuronal proliferation (Moon et al., 2013) , differentiation (Forouzanfar et al., 2015) , and neurotrophin synthesis (Wrann et al., 2013) , conferring neuroprotection against amyloid peptide 1-42 (Aβ 1-42 ) in mice (Xia et al., 2017) , and antidepressant-like effect in rats subjected to unpredictable mild stress (Wang and Pan, 2016) .
Similarly to physical exercise, peripheral delivery of FNDC5 to the liver via adenoviral vectors (resulting in elevated blood irisin levels) induces expression of brain-derived neurotrophic factor (BDNF) and other neuroprotective genes in the hippocampus of mice (Wrann et al., 2013) . In line with this, the genetic polymorphism in BDNF (BDNF Met/ Met ) abrogated the ability of exercise to cause antidepressant-like effect and to increase BDNF and FNDC5 mRNA levels in the dentate gyrus of the hippocampus (Ieraci et al., 2016) .
Although these studies suggest a relationship between FNDC5 and BDNF, there are no studies exploring the effects of the central administration of irisin or BDNF in predictive tests of antidepressant properties paralleled with the gene expression of PGC-1α, FNDC5 and BDNF in the hippocampus and prefrontal cortex, two brain regions closely implicated in depression (Kang et al., 2007; Schmaal et al., 2016) . Therefore, the present study tries to minimize this gap by exploring this issue.
Materials and methods

Animals
Male C57BL/6 mice (25-35 g, 60-70 days of age) housed at polypropylene cages (12 animals) under a 12/12 h light/dark cycle (lights on at 07:00 h) and temperature (21 ± 1°C) were used in this study. Mice received free access to standard laboratory food and tap water and were allowed to adapt at least 7 days prior to the experimental protocol onset. All manipulations were performed between 14:00 and 17:00 h, with each animal used only once. All procedures in this study were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Ethics Committee of the Institution. All efforts were made to minimize animals suffering and to reduce the number of animals used in the experiments.
Drugs and treatment
Irisin human recombinant (Caymam, MI, USA) and BDNF human recombinant (Prospec, NJ, USA) were used in the experiments. Irisin, BDNF or vehicle were administered by intracerebroventricular (i.c.v.) route using a micro syringe 50 μl (Hamilton) connected to a 26-gauge stainless-steel needle that was inserted perpendicularly 2 mm deep through the skull according to the procedure originally described (Laursen and Belknap, 1986) and adapted by Cunha et al. (2016a) . The animals were anesthetized with isoflurane for 15 s and then gently restrained by hand for i.c.v. injections. Asepsis of the injection site was carried out using gauze embedded in 70% ethanol. Right after anesthesia (i.e. just the necessary for postural reflex loss), the needle was inserted unilaterally 1 mm to the midline point equidistant from each eye, at an equal distance between the eyes and the ears and perpendicular to the plane of the skull. A volume of 3 μl of sterile saline containing the drugs was injected directly into the lateral ventricle, at the following coordinates from bregma: anterioposterior-(AP) 0.1 mm; mediolateral (ML) 1 mm; and dorsoventral (DV) 3 mm. Mice exhibited normal behavior within 1 min after injection. After experiments, all animals were decapitated and their brains were examined freshly. Results from mice presenting misplacement of the cannula or any sign of cerebral hemorrhage were excluded from the statistical analysis (overall < 5% of the total animals used).
Experimental design
In the first set of experiments, irisin (0.1-1 ng/mouse, i.c.v.), BDNF (0.25 μg/mouse, i.c.v.) or vehicle (NaCl 0.9%) were administered 1 h before the behavioral paradigms: open field test (OFT), tail suspension test (TST) or forced swim test (FST). In another set of experiments, irisin (1 ng/mouse, i.c.v.) was administered at different time points (30 min, 1, 6, or 24 h before the behavioral tests) in independent groups of animals. The dose of irisin was selected based on a pilot study carried out by our research group. BDNF was administered by i.c.v. route at the dose of 0.25 μg/mouse 1-6 h before the TST or OFT. The BDNF dose was chosen based on literature data (Sirianni et al., 2010; Valvassori et al., 2015) . Animals were euthanized immediately after the behavioral tests. The hippocampi and prefrontal cortices were dissected from the brain and kept at −80°C for further biochemical analysis.
Tail suspension test (TST)
This test aims to screen for potential antidepressant drugs and consists to submit mice to a short-term inescapable stress induced by tail suspension. Animals tend to develop an immobile posture; antidepressant drugs decrease the immobility time in this test. Mice both isolated acoustically and visually were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tail tip (Steru et al., 1985) . Total immobility time was registered during 6 min. Mice were considered immobile only when they hung passively and completely motionless.
Forced swim test (FST)
FST is a test used for evaluation of antidepressant efficacy of new compounds, and experimental manipulations that are aimed at preventing depressive-like states (Porsolt et al., 1977) . Mice were individually forced to swim in an open cylindrical container (diameter 10 cm, height 25 cm), containing 19 cm of water (depth) at 25 ± 1°C. The total immobility time was recorded during a 6-min session. Each mouse was judged to be immobile when it ceased struggling and remained floating motionless in the water, making only those movements necessary to keep its head above water. After the initial 2-3 min of vigorous activity, animals adopted an immobility behavior and the classical antidepressants decrease their immobility time, suggesting an antidepressant-like behavior.
Open field test (OFT)
In order to rule out a false positive result in the TST and FST tests due to hyperlocomotion, the OFT was performed. In this test, the locomotor activity was assessed as previously described (Cunha et al., 2016b) . The apparatus consisted of a wooden box measuring 40 × 60 × 50 cm high. The arena floor was divided into 12 equal squares. The number of squares crossed with all paws (crossings) was counted during a 6-min session. Furthermore, the numbers of rearing (vertical exploration), self-grooming and fecal boli as well as the time spent in the center of apparatus were also measured.
BDNF levels
BDNF levels were measured by ELISA using a BDNF Emax Immuno Assay System kit (Promega, Madison, WI, USA) according to manufacturer's guideline. Briefly, 96-well plates were incubated with a monoclonal anti-BDNF antibody in carbonate buffer (pH = 9.7) overnight at 4°C. The plates were then washed with PBS-Tween-20 (PBST; 8 mM sodium phosphate dibasic heptahydrate, 32 mM sodium phosphate monobasic monohydrate, 240 mM NaCl, 0.05% Tween-20), and blocked for 1 h at room temperature. A standard curve was prepared with BDNF. Tissue samples were diluted in blocking buffer (Promega) and subsequently added to the remaining wells (100 μl per well). The plates were incubated for 2 h under shaking at 25°C. Subsequently, the microplates were washed five times with PBST and a polyclonal anti-human BDNF was added to wells that were then incubated for 2 h at room temperature. After five washes with PBST, a horseradish peroxidase (HRP)-conjugated anti-IgY antibody was added to the plate wells that were incubated for additional 1 h at room temperature. After five more washes with PBST, a peroxidase substrate was added for 15 min. The reaction was stopped by adding 1 N HCl solution and absorbance was read in a microplate reader (Multireader Infinite M200 TECAN) at 450 nm. BDNF levels (expressed as pg/mg protein) were calculated from the standard curve prepared for each plate.
RNA extraction, cDNA synthesis, and quantitative real-time PCR
Hippocampus and prefrontal cortex were collected and frozen at −80°C. Total RNA was extracted with Trizol reagent (Invitrogen, USA) and samples were treated with DNAse I, Amplification Grade (Invitrogen, USA), for genomic DNA removal. Total RNA was frozen at −80°C until use. Complementary DNA (cDNA) synthesis was carried out with 0.4 μg of each RNA sample and reverse transcribed to cDNA using High Capacity cDNA Reverse Transcription Kit (Invitrogen, CA, USA). Reaction mix, in a final volume of 20 μl, was incubated at 25°C for 10 min, at 48°C for 1 h, and then at 95°C for 5 min. The obtained cDNA solution was diluted 1:5. Quantitative real-time (qRT-PCR) was performed using 0.3 mM of each primer, 5 μl of Maxima SYBR® Green/ ROX qPCR Master Mix 2× (Thermo Fisher Scientific, São Paulo, Brazil) and 2 μl of each diluted cDNA, in a 7900 HT Fast Real-Time PCR System (Thermo Fisher Scientific). Amplification conditions were 50°C for 2 min, 90°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The primers used were designed with Primer Express software version 3.0 (Applied Biosystems, USA) and the sequences are described subsequently: BDNF forward (CATAGACAAAAGGCACTGGA ACTC) and reverse (TAAGGGCCCGAACATACGAT); FNDC5 forward ( GGCTGGGAGTTCATGTGGAA) and reverse (TGGGAAGCGGTTATCTTT GCT), PGC-1α forward (ATGTGACTGGGGACTGTAGTAAGA) and reverse (GCAGCACACTCTATGTCACTC), β-actin forward (AAATCGTGC GTGACATCAAAGA) and reverse (GCCATCTCCTGCTCGAAGTC). Results were analyzed by the software Sequence Detection Systems (SDS) version 2.4 software (Applied Biosystems, CA, USA). Primers efficiency was tested using the standard curve method. For this purpose, a serial dilution (1:3, 1:7, 1:15, 1:31, 1:63) was made from a single cDNA sample consisted of a pool of all cDNAs from the different treatments. Only primers that showed efficiencies between −2.9 and −3.3 were used. Specificity of the qPCR products was analyzed by a dissociation curve performed after amplification, observing a single peak at the expected Tm. Furthermore, stability of the control gene was verified by RefFinder online tool. Results were analyzed by standard curve based method (Larionov et al., 2005) in which arbitrary numbers were given for each one of the five points in a logarithmic base 10 scale. Controls were confronted against the curves resulting in a relative value of amplicons. Results were normalized by β-actin values and converted into percentage considering control values as 100%.
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate the normality assumption of behavioral and biochemical data. Results were expressed as mean + standard error of the mean (S.E.M.), and comparisons between experimental and control groups were performed by one-way (dose-response curve and biochemical analyses) or two-way (time-response curve of irisin or BDNF in the behavioral tests) analysis of variance (ANOVA) followed by Newman-Keuls post-hoc test. A value of p < 0.05 was considered to be statistically significant.
Results
Effect of irisin administration in the behavior of mice submitted to TST, FST and OFT
The effects of central administration of irisin (0.5-1 ng/mouse) in the immobility time of mice subjected to the TST and FST are shown in Fig. 1A and B, respectively. One-way ANOVA revealed that mice treated with irisin presented a significant reduction in the immobility time in the TST [F (3, 32) = 6.21, p < 0.01] and FST [F (3, 25) = 4.75, p < 0.01], when compared to the control group. Further post-hoc analyses revealed that irisin reduced the immobility time in both tests at the doses of 0.5 ng/mouse (p < 0.05) and 1 ng/mouse (p < 0.01).
The effect of irisin administration at doses of 0.1, 0.5, and 1 ng/ mouse on the locomotor activity of mice was assessed in the OFT. (Fig. 2D-E, respectively) .
Considering the absence of literature data regarding the possible effect of irisin in the TST, the dose of 1 ng/mouse i.c.v. (most significant effect in the TST) was chosen for a time-course experiment. Irisin effect in the TST was evaluated 30 min, 1, 6 and 24 h after its administration in independent groups. The results depicted in Fig. 3A shows that irisin reduced the immobility time in the TST up to 6 h after its administration. A two way-ANOVA revealed a significant effect for treatment [F (1, 50) = 13.00, p < 0.05], and for time [F (3, 50) = 2.32, p < 0.01], but not for treatment × time interaction [F (3, 50) = 2. 13, p = 0.10]. On the other hand, the irisin administration did not alter the number of crossings in the OFT at any time point tested (Fig. 3B) . A two-way ANOVA revealed a significant effect of time [F (3, 45) = 13.52, (Fig. 3B ).
Effect of irisin administration on PGC-1α and FNDC5 gene expression
The effects of acute central administration of irisin to promote changes in the gene expression of PGC-1α, FNDC5 in the hippocampus and prefrontal cortex of mice were investigated 1 and 6 h after the TST. Irisin administration increased the PGC-1α mRNA in the hippocampus 6 h after the treatment as compared to the respective control group [F (2, 11) = 51.10, p < 0.01, Fig. 4A ]. Interestingly, FNDC5 mRNA in the hippocampus decreased 1 h after the treatment with irisin and increased 6 h after the treatment as compared to 1 h group [F (2, 12) = 17.60, p < 0.01, Fig. 4C ]. Irisin also decreased PGC-1α mRNA in prefrontal cortex of mice 1 h after its administration and increased PGC-1α mRNA 6 h after treatment [F (2, 11) = 66.60, p < 0.01, Fig. 4B ]. Regarding FNDC5 mRNA expression, irisin administration decreased the gene expression 1 h after treatment in both structures, an action that remained statistically significant until 6 h after drug administration in the prefrontal cortex [F (2, 10) = 23.74, p < 0.01, Fig. 4D ].
3.3. Influence of irisin administration on BDNF gene expression and BDNF protein levels Fig. 5A shows that hippocampal BDNF mRNA was decreased 1 h after the treatment with irisin and increased 6 h after treatment as compared to the control group [F (2, 15) = 11.91, p < 0.01]. In the prefrontal cortex, BDNF mRNA was reduced in both evaluated time points (1 and 6 h after treatment), as compared to the respective control group BDNF mRNA [F (2, 11) = 24.47, p < 0.01, Fig. 5B ]. In addition, as depicted in Fig. 5C -D, one-way ANOVA revealed that administration of irisin 1-6 h before BDNF measurements did not alter the levels of this neurotrophin in the hippocampus and prefrontal cortex of mice [F (2, 19) = 1.38, p = 0.27; F (2, 20) = 0,85, p = 0.44, respectively]. 3.5. Influence of BDNF administration on PGC-1α and FNDC5 mRNA levels BDNF administration reduced the PGC-1α mRNA levels in the hippocampus 6 h after treatment, but it did not affect PGC-1α mRNA levels when administered 1 h before the analysis, as shown in Fig. 7A [F (2, 13) = 5.90, p < 0.05]. In addition, FNDC5 mRNA levels were increased in the hippocampus 1 or 6 h after BDNF administration [ Fig. 7C , F (2, 16) = 6.32, p < 0.01]. However, as depicted in Fig. 7B and Fig. 7D both mRNA PGC1-α and FNDC5 expression were reduced in the prefrontal cortex 1 h after treatment and their expression was maintained decreased until 6 h after BDNF administration [FNDC5 mRNA F (2, 15) = 11.06, p < 0.01; PGC-1α mRNA F (2, 13) = 7.89, p < 0.01].
Influence of BDNF administration on BDNF gene expression and BDNF protein levels
The effects of BDNF administration on the levels of BDNF mRNA and BDNF protein are shown in Fig. 8 . In the prefrontal cortex [F (2, 12) = 10.28, p < 0.01; Fig. 8B ], but not in the hippocampus [F (2, 13) = 1.77, p = 0.21; Fig. 8A ], the administration of BDNF at both time points reduced BDNF mRNA. However, as shown in Fig. 8C and D no alteration on BDNF levels was observed in the hippocampus and prefrontal cortex following BDNF administration (1 or 6 h) [F (2, 16) = 0.40, p = 0.67; F (2, 16) = 1.82, p = 0.19, respectively]. Fig. 4 . Effect of administration of irisin (1 ng/mouse, i.c.v.) on mRNA PGC-1α expression in the hippocampus (A) and prefrontal cortex (B) as well as mRNA FNDC5 expression in the hippocampus (C) and prefrontal cortex (D) 1 or 6 h after irisin administration. Data are expressed as means + S.E.M. and results were analyzed by one-way ANOVA followed by the Newman-Keuls post-hoc test. **p < 0.01 as compared with the respective vehicle-treated group. ## p < 0.01 when mRNA FNDC5 was evaluated 6 h after treatment as compared with 1 h.
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Discussion
In the present study, we observed that irisin administered centrally to mice was able to elicit an antidepressant-like behavior in two predictive tests of antidepressant potential: TST and FST. To the best of our knowledge, this is the first study showing that central administration of irisin elicited antidepressant-like behaviors. In addition, central administration of BDNF caused a similar effect, and both treatments altered the gene expression of PGC-1α, FNDC5 and BDNF, but did not alter the levels of BDNF. A summary of these neurochemical results is shown in Table 1 . Altogether the results suggest that irisin acts in the central nervous system modulating mood-related behaviors, similarly to BDNF.
Clinical studies are discrepant regarding the involvement of irisin on mood regulation. A study by Papp et al. (2017) showed that impaired mood in chronic obstructive pulmonary disease patients are associated with lower serum irisin levels, while a study by Hofmann et al. (2016) demonstrated that plasma irisin levels are not associated with depressive symptoms, anxiety and perceived stress in obese women. Regarding preclinical studies, recent studies showed that central administration of irisin caused some effects on rat behavior, including increased feeding and hyperlocomotion (Tekin et al., 2017; Zhang et al., 2015) . In addition, irisin administered subcutaneously was able to prevent chronic unpredictable stress (CUS)-induced anhedonic behavior in the sucrose preference test and depressive-like behavior in the FST in rats (Wang and Pan, 2016) . However, in the above-mentioned study the effect of irisin in the FST was not investigated in animals not submitted to CUS.
Taking into account the need of more studies investigating the effect of irisin in predictive tests for antidepressant drug, we decided to investigate the effect of central administration of irisin on the behavior of mice submitted to the FST and TST, two behavioral paradigms widely used for screening antidepressant drug activity. The ability of irisin (0.5 and 1 ng/mouse) to reduce immobility time, a result indicative of an antidepressant-like profile, was observed. Both doses of irisin produced similar reductions in the immobility time in the TST and FST, but the significance level was greater at the higher irisin dose. In the TST, this effect persisted up to 6 h after irisin administration. The absence of behavioral alterations in the TST 24 h after irisin administration is an indicative that its antidepressant-like effect is not persistent, similar to the behavioral profile observed with the administration of conventional antidepressants (Bettio et al., 2014; Neis et al., 2016) . No alteration in Fig. 5 . Effect of administration of irisin (1 ng/mouse, i.c.v.) on mRNA BDNF expression in the hippocampus (A), prefrontal cortex (B), and BDNF levels in the hippocampus (C), and prefrontal cortex (D) 1 or 6 h after irisin administration. Data are expressed as means + S.E.M. for mRNA gene expression, and pg/mg protein for protein levels. Results were analyzed by one-way ANOVA followed by the NewmanKeuls post-hoc test. *p < 0.05, ** p < 0.01 as compared with the respective vehicle-treated group. ## p < 0.01 when mRNA BDNF was evaluated 6 h after treatment as compared with 1 h. Fig. 6 . Effect of BDNF (0.25 μg/mouse, i.c.v.) administration in the TST (A) and number of crossings in the OFT (B) 1 and 6 h after BDNF administration. Data are presented as means + S.E.M. and results were analyzed with a two-way ANOVA followed by the Newman-Keuls post-hoc test. **p < 0.01 as compared with the respective vehicle-treated group.
A. Siteneski et al. Progress in Neuropsychopharmacology & Biological Psychiatry 84 (2018) 294-303 the locomotor activity was observed in mice treated with irisin in the open-field test, ruling out the possibility that the results obtained in TST and FST are due to a psychostimulant effect of irisin. The absence of alterations in the locomotor activity contrasts with the results reported by Zhang et al. (2015) who showed that a single high dose of irisin (1.5-2.5 μg/kg, i.c.v.) caused an abrupt and transient increase in locomotor activity of rats. These differences in locomotion are likely due to the doses used and/or specie. In the OFT, anxiety-related parameters (time spent in the center of apparatus, number of grooming, and fecal boli) were also examined. Irisin administration was capable of increasing time spent in the center of the open-field arena, a finding suggestive of anxiolytic effect of this myokine. This assumption was reinforced by the fact that irisin also decreased number of groomings and fecal boli in the open field test. Interestingly, the anxiolytic-like profile of irisin was observed at the doses of 0.5 and 1.0 ng/mouse, the same ones that elicited antidepressant-like effects. Similar to the result observed in the FST and TST, the behavioral alterations suggestive of anxiolytic effect were of Fig. 7 . Effect of BDNF (0.25 μg/mouse, i.c.v.) administration on mRNA PGC-1α expression in the hippocampus (A) and prefrontal cortex (B), as well as mRNA FNDC5 expression in the hippocampus (C) and prefrontal cortex (D) 1 or 6 h after BDNF administration. Data are expressed as means + S.E.M. and results were analyzed by one-way ANOVA followed by the Newman-Keuls post-hoc test. *p < 0.05, **p < 0.01 as compared with the respective vehicle-treated group. Fig. 8 . Effect of BDNF (0.25 μg/mouse, i.c.v.) administration on mRNA BDNF expression in the hippocampus (A), prefrontal cortex (B), and BDNF levels in the hippocampus (C) and prefrontal cortex (D) 1 or 6 h after BDNF administration. Data are expressed as means + S.E.M. for mRNA gene expression, and as pg/mg protein for protein levels.
Results were analyzed by one-way ANOVA followed by the Newman-Keuls post-hoc test. *p < 0.05,**p < 0.01 as compared with the respective vehicle-treated group. similar magnitude at both irisin doses. However, literature data are not in agreement with our findings. The frequency of grooming and time spent grooming were reported to be unaltered in rats treated with a single i.c.v. dose of irisin as compared with controls (Zhang et al., 2015) . In addition, a recent study reported an anxiogenic effect of irisin administered intracerebroventricularly to rats (Chiavaroli et al., 2017) . Considering the discrepancies between our results and those in rats, it seems that rats and mice produce different anxiety-related behavioral patterns following central irisin administration. Exercise has been reported to induce expression of the transcriptional coactivator PGC-1α in muscle. The possible role of PGC-1α in mood regulation was suggested by a study which reported that mice in which PGC-1α was overexpressed in muscle exhibited resilience to chronic mild stress-induced depression (Agudelo et al., 2014) . Moreover, PGC-1α −/− mice have a reduction in FNDC5 expression in the cerebral cortex, as compared to wild-type mice (Wrann et al., 2013) . Therefore, the effect of central irisin administration on PGC-1α and FNDC5 mRNA expression in the hippocampus and prefrontal cortex of mice was investigated in the present study. Irisin decreased PGC-1α mRNA expression in the prefrontal cortex after 1 h and increased PGC-1α mRNA expression in the hippocampus and prefrontal cortex 6 h after its administration. Irisin administration also decreased FNDC5 mRNA expression in both brain structures. In the hippocampus, this reduction was transient, since it was not observed 6 h after irisin administration. On the other hand, in the prefrontal cortex the reduction was maintained up to 6 h. Although PGC-1α mRNA expression was not altered (1 h in the hippocampus) or even decreased (1 h in the prefrontal cortex), its expression was increased 6 h after the administration of irisin in both brain structures. Of note, increased PGC-1α expression in several brain regions (brain stem, cerebral cortex, frontal lobe, hippocampus, hypothalamus, and midbrain) and soleus muscle was reported in mice subjected to exercise training for 8 weeks (Steiner et al., 2011) . Regarding FNDC5 expression, and absence of alteration (6 h, in the hippocampus) or reduction in the expression of this gene (1 h in the hippocampus, 1 and 6 h in the prefrontal cortex) was observed following irisin administration. Interestingly, literature data report that irisin increase is not always associated with increased FNDC5 expression in muscle, a finding that is in agreement with the results reported herein (Fain et al., 2013; Tiano et al., 2015) . Irisin has been proposed to exert beneficial effects on mood by inducing the expression of BDNF in some brain regions (Papp et al., 2017) . This proposal was based mainly on the finding that mood disturbances in chronic obstructive pulmonary disease patients were associated with lower serum irisin levels and this association was stronger among patients in the lower 50% BDNF levels, but it became weaker for patients in the higher 50% BDNF levels (Papp et al., 2017) . Hippocampal BDNF was shown to be upregulated both by peripheral delivery of FNDC5 to the liver via adenoviral vectors and exercise (Wrann et al., 2013) . In addition, FNDC5 overexpression increased BDNF expression, whereas FNDC5 knockdown reduced BDNF levels in cortical neurons (Wrann et al., 2013) . In the present study, the effect of central irisin administration on the BDNF mRNA expression and protein levels were also examined. In the hippocampus, irisin decreased BDNF mRNA expression 1 h after its administration, but increased the expression of this neurotrophin after 6 h. In the prefrontal cortex, BDNF mRNA expression was decreased at both time periods, although no alteration in BDNF protein levels was observed at any time periods employed in the present study, probably due to the fact that these time periods are not enough to alter protein translation. In the prefrontal cortex (1 h and 6 h) and hippocampus (1 h) the decrease in BDNF mRNA expression was paralleled with a reduction on FNDC5 mRNA, a result that is in line with the fact that FNDC5 is a positive regulator of BDNF expression (Wrann et al., 2013) .
BDNF has received great attention for its role in neuroplasticity that may be responsible for its antidepressant properties (Schmidt and Duman, 2010) . We showed that central BDNF administration, similar to irisin, produced a robust antidepressant-like effect in the TST when administered 1-6 h before the test. Of note, this effect cannot be attributable to a psychostimulant effect of BDNF. Indeed, BDNF administration caused hypolocomotion in the OFT, which may have caused underestimation of the BDNF ability to reduce immobility time in the TST. Similar to our results, BDNF administered to the hippocampus significantly decreased the immobility time in rats submitted to FST as compared to control group (Shirayama et al., 2002; Sirianni et al., 2010) . The study by Shirayama et al. (2002) showed that the effect of BDNF in the FST was observed 3 days after its infusion. Interestingly, a study demonstrated that BDNF administered by i.c.v. route produced antidepressant-like effects in the modified rat FST, reducing immobility and increasing swimming, effects that persisted at least 6 days after its administration (Hoshaw et al., 2005) . Of particular relevance to the behavioral effects found here, BDNF is considered a key mediator of the clinical efficacy of antidepressants (Bjorkholm and Monteggia, 2016) .
BDNF incubation reduced FNDC5 gene expression in primary cortical neurons and this effect was abolished by pre-incubating cortical neurons with K252a (a TrkB receptor antagonist), suggesting a homeostatic FNDC5/BDNF feedback loop (Wrann et al., 2013) . Here, we investigated the effect of BDNF administration on PGC-1α, FNDC5, and BDNF gene expression in the hippocampus and prefrontal cortex. We showed herein that BDNF decreased PGC-1α, FNDC5, and BDNF mRNA expression in the prefrontal cortex when administered 1-6 h before the analyses. In addition, BDNF increased FNDC5 (1-6 h) and decreased PGC-1α (6 h) gene expression, but did not alter BDNF expression in the hippocampus. Conversely, FNDC5 expression was reduced in hippocampal neurons exposed to BDNF (Wrann et al., 2013) and a previous study indicated that BDNF administration by i.c.v. route (two administrations 3 days apart, 300 ng/site) increased BDNF mRNA in the hippocampus, but not in the prefrontal cortex in mice of antidepressant sensitive catalepsy strain, 21 days after its administration (Tikhonova and Kulikov, 2012) . Furthermore, Valvassori et al. (2015) showed that BDNF (0.25 μg/rat) increased BDNF levels in the hippocampus and frontal cortex of rats 7 days after its i.c.v. administration. In our study, BDNF administered centrally failed to alter BDNF protein levels both in the hippocampus and prefrontal cortex, but the reasons for the lack of alterations in brain BDNF levels are presently unknown. It is possible that the observed behavioral outcomes of BDNF treatment do not necessarily reflect alterations in the levels of this neurotrophin in specifics brain regions, but instead changes in downstream cascades implicated in behavioral responses. Discrepancies between our results and literature data might be due to the different species and/or strain used as well the time period of the analyses (short time period in the present study as compared to the literature data).
Finally, it is interesting to note that irisin levels follow a day-night rhythm with its lowest levels early in the morning and its peak levels around 9:00 PM (Anastasilakis et al., 2014) . BDNF expression was also reported to exhibit oscillations related to circadian variations (peak levels around 8:00 PM) in male mice (Yi et al., 2015) . Therefore, it is 
A. Siteneski et al. Progress in Neuropsychopharmacology & Biological Psychiatry 84 (2018) [294] [295] [296] [297] [298] [299] [300] [301] [302] [303] possible that greater variations in the neurochemical parameter evaluated would have been obtained if the analyses were performed at night when the animals are more active.
Conclusion
Collectively, our results demonstrate that irisin administered centrally is able to produce antidepressant-like behavior, similar to the behavioral profile elicited by BDNF. In addition, we further show that irisin may modulate the gene expression of PGC-1α, FNDC5 and BDNF in the hippocampus and prefrontal cortex in a time-dependent manner, further reinforcing the pivotal role of these genes in mood regulation.
